Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-synuclein is a 140-amino acid protein encoded by the SNCA gene, primarily localized in the presynaptic terminals of the central nervous system where it modulates synaptic vesicle trafficking and neurotransmitter release (UniProt P37840). In synucleinopathies such as Parkinson's disease, Dementia with Lewy bodies, and Multiple System Atrophy, the protein misfolds into toxic oligomers and insoluble beta-sheet-rich fibrils that accumulate as Lewy bodies. These aggregated forms are thought to drive neurodegeneration by disrupting cellular membranes, impairing mitochondrial function, and spreading between neurons in a prion-like fashion. Therapeutic strategies targeting these aggregates aim to halt disease progression by inhibiting the aggregation process, neutralizing spreading fibrils with antibodies, or enhancing cellular clearance mechanisms. While several monoclonal antibodies and small molecules are in clinical development, challenges remain regarding blood-brain barrier penetration and the potential impact on the protein's normal physiological roles.
The mechanism of action for drugs targeting alpha-synuclein aggregates involves several approaches: passive immunotherapy using monoclonal antibodies to bind extracellular aggregates and prevent their uptake by neighboring neurons (seeding), small molecules that stabilize the monomeric form or disrupt the formation of toxic oligomers and fibrils, and agents that promote the degradation of existing aggregates through the lysosomal or autophagic pathways.
7 more in the full profile.
Source types: Peer-reviewed publication · Trial registry. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-synuclein aggregate (α-syn) (α-syn).